PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
17-Jan-2023 Approval of GMP Registration by MHRA Celadon Pharmaceuticals Plc
17-Jan-2023 Full Year Trading update Spectral MD Holdings, Ltd
17-Jan-2023 Poolbeg announces strategic expansion of POLB 001 into oncology Poolbeg Pharma Plc
17-Jan-2023 Remote Patient Monitoring Users to Reach 115 Million Globally by 2027; Driven by Healthcare System Pressures Juniper Research
17-Jan-2023 Eckert & Ziegler Exceeds Forecast for the 2022 Financial Year According to Preliminary Figures Eckert & Ziegler Strahlen- und Medizintechnik AG
17-Jan-2023 SolasCure announces publication of toxicology and pre-clinical research programme as final patient is enrolled into pivotal clinical trial SolasCure
17-Jan-2023 Enalees appoints Eric Germain as managing director Andrew Lloyd Associates
17-Jan-2023 InnoScot Health hails ‘fantastic’ funding for MHRA projects InnoScot Health
17-Jan-2023 Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality Avectas
17-Jan-2023 ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002 ImmunOs Therapeutics
17-Jan-2023 Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer Pan Cancer T
17-Jan-2023 Industry-First Cancer Screening Technology Boosted by Biomedical Grant Funding Medicines Discovery Catapult
17-Jan-2023 GPCR Therapeutics Announces Launch of US Phase 2 Trial of GPC-100 in Multiple Myeloma GPCR Therapeutics
17-Jan-2023 Vésale Bioscience receives €1.8M grant from European Innovation Council for PhageDiag project Andrew Lloyd Associates
17-Jan-2023 Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan Kinarus Therapeutics Holding AG
17-Jan-2023 Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom Relief Therapeutics Holding SA
16-Jan-2023 The Scottish Medicines Consortium recommends Merck’s TEPMETKO® (tepotinib) as the first oral MET inhibitor treatment option for advanced NSCLC adult patients with METex14 skipping alterations Merck
16-Jan-2023 PharmiWeb.Jobs Welcomes Alexion Alexion
16-Jan-2023 EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer   Andrew Lloyd Associates
16-Jan-2023 CD Formulation Offers 16 types of Food Ingredients as Raw Materials to Manufacture Health Care Products CD Formulation